Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/9/14  and contains information from public web pages.

Scientific Advisory Board Member

Phone: (215) ***-****  HQ Phone
Sbarro Health Research Organization
Bio-Life Science Bldg. Ste. 431 1900 N 12Th St.
Philadelphia , Pennsylvania 19122
United States

Company Description: Sbarro Health Research Organization is committed to excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD. Ph.D.
  • M.D.
  • Ph.D.
  • MD
  • PhD
  • M.D. degree summa cum laude
    University of Naples
10 Total References
Web References
S.H.R.O. Institution :: Administration
www.shro.org, 9 Feb 2014 [cached]
Michele Maio, MD. Ph.D. Director Division of Medical Oncology and Immunotherapy University Hospital of Siena, Siena, Italy
S.H.R.O. Press Room :: Press Releases
www.shro.org, 9 Feb 2014 [cached]
Michele Maio, a member of the scientific board of the Sbarro Health Research Organization (SHRO) and director of the Center for Cancer Immunotherapy of Siena, in collaboration with researchers from Human Health Onlus Foundation (HHF) of Spoleto, led the project Nibit M1, using for the first time Ipilimumab in combination with a chemotherapeutic agent (fotemustine) to combat cancer. Ipilimumab has recently been approved by the FDA for the treatment of skin cancer.
...
SHRO Scientific Advisory Board Member Michele Maio announces trials for promising new cancer treatment
S.H.R.O. Research - Scientists
www.shro.org, 16 Nov 2007 [cached]
Michele Maio, M.D., Ph.D.
S.H.R.O. Board of Directors: DirectorUniversity Hospital of Siena, Siena - Italy
...
Michele Maio, MD, PhD, Chairs the Division of Medical Oncology and Immunotherapy at the University Hospital of Siena, Italy, since 2003 and is consultant for cancer bioimmunotherapy at the National Cancer Institute of Aviano, Italy where he has headed the Cancer Bioimmunotherapy Unit from 1987 to 2003.He is Lecturer in Immunology at the University of Udine, Italy and Adjunct Professor, at the College of Science and Biotechnology of Temple University, Philadelphia, PA, U.S.A.
Michele Maio, MD, PhD
E-mail: Mmaio@cro.it
Dr. Maio serves on the Editorial Boards of Seminars in Oncology, Journal of Immunotherapy, Women's Oncology Reviews, The Journal of Translational Medicine, Journal of Experimental and Clinical Cancer Research (Reviews Editor), Supportive and Palliative Cancer Care and he has been an invited lecturer at more than 130 scientific meetings in Italy and abroad.
Born in Naples, Italy, Dr. Maio earned his M.D. degree summa cum laude from the University of Naples in 1982.He is Board Certificated in Hematology (University of Rome, Italy) and Oncology (University of Naples, Italy), and has joined as post-doctoral fellow (1983-1987) and as Adjunct Associate Professor of Microbiology and Immunology (1988-2000) the Department of Microbioolgy and Immunology of New York Medical College, Valhalla, NY.
His clinical research activities focus on the pre-clinical development and clinical application of new strategies of immunologic and biologic therapy of cancer, with major emphasis on solid malignancies.Basic research interests concern the biologic and molecular mechanisms regulating tumor-host interactions.His research is funded by several national and international granting agencies.
Dr. Maio is member of the American Association for Cancer Research, American Association of Clinical Oncology, Italian Cooperative Group for Immunology, Italian Tumor Society, European Organization for Research and Treatment of Cancer-Melanoma Group, Italian Mesothelioma Group, and of the Scientific Advisory Board of the Sbarro Health Research Organization.
More than 100 peer-reviewed scientific papers have been authored by Dr. Maio, along with several monographs, books and book chapters.
S.H.R.O. Welcome
www.shro.org, 28 June 2011 [cached]
Michele Maio, a member of the scientific board of the Sbarro Health Research Organization (SHRO) and director of the Center for Cancer Immunotherapy of Siena, in collaboration with researchers from Human Health Onlus Foundation (HHF) of Spoleto, led the project Nibit M1, using for the first time Ipilimumab in combination with a chemotherapeutic agent (fotemustine) to combat cancer. Ipilimumab has recently been approved by the FDA for the treatment of skin cancer.
S.H.R.O. Institution - Administration
www.shro.org, 16 Nov 2007 [cached]
Michele Maio, MD. Ph.D. Director Division of Medical Oncology and Immunotherapy University Hospital of Siena, Siena - Italy
Other People with the name "Maio":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304